What Drugs Are Stelara and Humira?
Stelara (ustekinumab) targets IL-12 and IL-23 cytokines, treating plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Humira (adalimumab) is a TNF-alpha inhibitor for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.[1]
How Do They Compare for Psoriasis Treatment?
Stelara often clears skin better in head-to-head trials. In the 2019 UNITE study, 76% of Stelara patients achieved PASI 90 (90% skin clearance) at week 12 versus 46% on Humira. Stelara requires fewer doses (every 12 weeks after loading) compared to Humira's weekly or biweekly injections.[2]
Head-to-Head Results in Psoriatic Arthritis?
Stelara shows similar joint efficacy to Humira but superior skin clearance. The PSUMMIT trials found Stelara reduced ACR20 scores by 42-50% at week 24, matching Humira's results, while achieving higher PASI 75 rates (67-71% vs. Humira's 50-60% in similar studies).[3]
Which Is Better for Inflammatory Bowel Disease?
Humira has broader approval and longer data for Crohn's and ulcerative colitis. Stelara matches or exceeds Humira in induction remission for Crohn's (IM-UNITI trial: 40% remission at week 8 vs. Humira's 30-40%), but Humira edges out in maintenance for some patients. Stelara works faster for ulcerative colitis induction.[4]
Side Effects and Safety Differences
Both carry infection risks, but Stelara has lower rates of serious infections (3.7% vs. Humira's 4.7% in psoriasis trials) and fewer injection-site reactions due to less frequent dosing. Humira links to higher tuberculosis reactivation risk as a TNF blocker. Long-term cancer risks appear similar.[1][5]
Cost and Dosing Schedules
Humira costs $6,000-$7,000 monthly before discounts; Stelara is similar at $5,500-$6,500 but cheaper long-term with IV induction plus quarterly subcutaneous doses versus Humira's ongoing weekly/biweekly shots. Biosimilars have slashed Humira prices (e.g., Amjevita at 85% less), while Stelara biosimilars launch in 2025.[6]
When Do Patents Expire?
Humira's main patents expired in 2023, enabling nine biosimilars in the US. Stelara's key composition patent ends January 2025, with litigation delaying full generic entry to 2033 in some cases.7 DrugPatentWatch.com | DrugPatentWatch.com
Sources
[1]: FDA Labels - Stelara | Humira
[2]: Journal of the American Academy of Dermatology (2019 UNITE study)
[3]: Annals of the Rheumatic Diseases (PSUMMIT I/II)
[4]: NEJM (IM-UNITI and UNIFI trials)
[5]: Stelara vs. Humira meta-analysis, Rheumatology (2022)
[6]: IQVIA pricing data (2024)